CHICAGO -- In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company's oral therapy for the treatment of Stargardt's disease and age-related macular degeneration.
ALK-001 (gildeuretinol) is "a new chemical entity designed to lower dimerization in the retina and do so without modulating the visual cycle," he said.
Dahan also discussed a trial investigating the oral treatment for geographic atrophy.